Peptides vs. TRT and HRT: How They Differ

Many clinics in Lakeland and across Polk County offer peptides alongside testosterone replacement therapy (TRT) and hormone replacement therapy (HRT). They are often marketed together, but they are different treatments with different evidence and rules. This guide explains how they compare, using FDA labels and FDA actions from 2025 and 2026.

Quick definitions

• TRT supplies testosterone, a steroid hormone, from outside the body. FDA-approved forms include gels, patches, a product applied to the gum or cheek, pills and injections.¹
• HRT, also called menopausal hormone therapy, is estrogen-based. FDA groups it into four types: estrogen plus a progestogen, estrogen alone, a progestogen for women with a uterus who take estrogen, and vaginal estrogen.²
• Peptides are short chains of amino acids. A few are FDA-approved drugs for specific uses. Most peptides sold by clinics are not FDA-approved for any use.³

What FDA has approved testosterone for

FDA says testosterone is approved only for men who lack or have low testosterone because of an associated medical condition.¹ A representative label lists conditions such as testicular failure, Klinefelter syndrome, chemotherapy damage, or pituitary and hypothalamus problems from tumors, injury or radiation.⁴

Low testosterone from aging alone is not an approved use. Labels say safety and effectiveness in “age-related hypogonadism” have not been established.⁴ FDA kept that limit in its 2025 label changes.¹ FDA had already urged caution in 2015 about using testosterone for low testosterone due to aging.¹

Testosterone label warnings

On February 28, 2025, FDA required changes for all testosterone products.¹

• Heart risk. FDA removed boxed-warning language on increased heart risk. The large TRAVERSE trial found no increase in heart events in men treated for hypogonadism.
• Blood pressure. FDA added a warning because blood-pressure studies “confirmed an increase in blood pressure with use of all testosterone products, class-wide.” Labels now say testosterone is not recommended for people with uncontrolled high blood pressure.⁴

Other label warnings include:⁴

• Blood clots. In TRAVERSE, clots in veins occurred in 1.7% of men on one testosterone gel versus 1.2% on placebo (a dummy treatment).
• A rise in red blood cells (hematocrit), which labels say should be checked before and after starting.
• Worse prostate-enlargement symptoms, lower sperm production, swelling and sleep apnea.
• For gels, a boxed warning: children who touched a user’s unwashed skin developed male-type changes.
• Testosterone is a Schedule III controlled substance. It has been abused at high doses with other steroids, which can cause serious heart and psychiatric problems.

Testosterone is also banned at all times in tested sport.⁵

Menopausal hormone therapy: the 2026 label changes

FDA says it has approved hormone therapies for moderate-to-severe hot flashes, vaginal dryness and discomfort, and preventing bone loss.²

On February 12, 2026, FDA approved label changes for six menopausal hormone products. Statements on heart disease, breast cancer and probable dementia were removed from the boxed warning. FDA started the process in November 2025, and 29 companies submitted changes. Not every product’s label had changed at that time.²

FDA also says randomized studies show lower overall death rates and fewer fractures in women who start HRT within 10 years of menopause, generally before age 60.² That is FDA’s own description; we did not review the underlying trials. The change does not mean HRT is risk-free. Ask your provider which warnings remain on the label of the product you are offered.

Where peptides fit

Peptides work on different signaling pathways, and anti-doping rules list them in a separate class from steroids.⁵ Some, such as sermorelin, tesamorelin and ipamorelin, are marketed for their effect on growth hormone.

Their regulatory status varies:

• Sermorelin was once FDA-approved as Geref for children with growth hormone deficiency and for a diagnostic test. The maker stopped selling it, and FDA withdrew the approvals effective June 18, 2009. FDA later said they were not withdrawn for safety or effectiveness reasons.⁶
• Ipamorelin is still on FDA’s significant-safety-risk list for outsourcing facilities (503B); its pharmacy (503A) nomination was withdrawn.³
• Kisspeptin-10 remains on FDA’s significant-safety-risk list for pharmacies (503A).³ See kisspeptin.

This research found no studies comparing peptides with TRT or HRT head to head. Most clinic peptides have no FDA label at all, so their risks are less well described. “Natural alternative” is a marketing phrase, not an evidence-based claim.

Florida’s telehealth law bars prescribing Schedule II drugs by video except in four settings.⁷ Testosterone is Schedule III, so that limit does not, by its own terms, apply to it. Federal DEA rules on prescribing controlled substances by telemedicine also apply, and we did not review them. Ask the prescriber how they follow current federal and Florida rules.

Questions to ask a provider

• What problem are we trying to address, and how did you confirm it?
• If you suggest testosterone, what medical condition is causing my low level?
• Why do you recommend a peptide, hormone therapy or both?
• Is the product FDA-approved or compounded? Which pharmacy makes it?
• How will you check my blood pressure, red blood cells and other labs?
• How could this affect fertility or my body’s own hormone production?
• What happens if I want to stop?

See our guide to your first peptide consultation, the anti-aging and muscle and performance goal pages, and Find a provider.